retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide: A Promising Option for

While exenatide provides clinically meaningful glycemic control, its impact on weight loss is relatively modest compared to more recent GLP-1R agents, resulting in less than 3 kg of weight reduction over a 30-week period (DeFronzo et al., 2005

Understanding one's genetic predispositions in GLP-1 and GIPR signaling pathways can support more informed discussions with providers about personalized dose selection, formulation choice (injectable vs

Tirzepatide is $289 monthly month-to-month through PlexusDx, compared to semaglutide at $189 monthly

Liraglutide (Victoza, Novo Nordisk) is a GLP-1 analogue emulating the human GLP-1 hormone [22, 23]